CN103933475A - Pharmaceutical composition for treating breast fibroadenoma, and preparation method and application thereof - Google Patents
Pharmaceutical composition for treating breast fibroadenoma, and preparation method and application thereof Download PDFInfo
- Publication number
- CN103933475A CN103933475A CN201410151841.2A CN201410151841A CN103933475A CN 103933475 A CN103933475 A CN 103933475A CN 201410151841 A CN201410151841 A CN 201410151841A CN 103933475 A CN103933475 A CN 103933475A
- Authority
- CN
- China
- Prior art keywords
- parts
- radix
- pharmaceutical composition
- preparation
- crude drug
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention provides a pharmaceutical composition for treating breast fibroadenoma, which is prepared from the following traditional Chinese medicinal materials in parts by weight: 15-18 parts of radix salviae miltiorrhizae, 12-15 parts of angelica, 15-18 parts of figwort, 12-15 parts of self-heal, 12-15 parts of Fructus Forsythiae, 10-12 parts of peach kernel, 6-9 parts of safflower, 4-6 parts of hemlock parsley, 10-12 parts of rhizoma bolbostemmae, 25-30 parts of raw oyster, 8-10 parts of rhizoma cyperi, 8-10 parts of radix curcumae, 8-10 parts of radix bupleuri, 8-10 parts of white peony root, 4-6 parts of balloonflower, 8-10 parts of radix achyranthis bidentatae and 4-6 parts of licorice. The invention also provides a preparation method and application of the pharmaceutical composition. The pharmaceutical composition has proper formula, can effectively treat breast fibroadenoma (or relieve state of illness), avoids the toxic or side effect in chemical medicines, and provides a new option for clinical application.
Description
Technical field
The present invention relates to a kind of pharmaceutical composition for the treatment of mammary gland fibroma.Belong to drug world.
Background technology
Mammary gland fibroadenoma is often called mastofibroma clinically, is to betide fibrous tissue and epithelioglandular Combination tumor in mammary glands in women lobule, and be a kind of modal excision of benign breast.The generation of mastofibroma is relevant with endocrine hormone imbalance, as relative in estrogen or absolute rising can cause primary disease, its reason is that fibrocyte increases extremely to estrogenic sensitivity in lobule, and what this may be with the amount of the contained estrogen receptor of fibrocyte or matter is extremely relevant.Estrogen is this pathogenetic stimulating factor, therefore it betide the ovarian function phase, after adolescence, the women at any age all can fall ill, but is apt to occur in its sexual function vigorous period most, thereby the young women of 18～25 years old is the most common.
Mastofibroma is apt to occur in upper quadrant outside breast, and approximately 75% is single-shot, and minority belongs to multiple (when while or difference).Except occurring lump, patient is conventionally without obvious subjective symptoms.Though it is optimum that mammary gland fibroadenoma belongs to, and has the possibility of cancerating, therefore once find, should active treatment.As a rule, lump in breast is the only symptom of primary disease, and its lump mostly is patient and finds unintentionally, generally painless, also do not change with menstrual cycle, but small part patient's mammary gland fibroadenoma and cyclomastopathy exist jointly, this situation can have premenstrual distending pain of the breast.
Though it is optimum that adenofibroma of breast belongs to, and has the possibility of cancerating, increase uncertain danger to patient, therefore answer active treatment.Western medical treatment mastofibroma one is excision, the 2nd, and hormonotherapy., excision not only makes patient be subject to the hardship of a cutter, and relapse rate is very high, and other positions of the breast of being everlasting occur again; And hormone therapy can produce again serious toxic and side effects.
On the whole mastofibroma be equivalent to the diseases such as the traditional Chinese medical science " nodules of the breast ", " nodule in the breast ", also has and be called " breast scrofula ", and its way of traditional Chinese medical science reply is from ancient times just rich and varied and curative effect is reliable, and have the history of putting into practice of two thousand years at least.By determination for the treatment of based on pathogenesis obtained through differentiation of symptoms and signs, can make different rule for the treatment of method for the treatment of; By the science compatibility of " medication is as used military forces ", can group make different effective good recipes.In addition, also have acupuncture and tuina-massage and style therapy of all kinds among the people, all can produce good effect.Thereby, in treatment, have no side effect than doctor trained in Western medicine resourcefulness and green natural undoubtedly.
Summary of the invention
Technical scheme of the present invention has been to provide a kind of pharmaceutical composition for the treatment of mastofibroma, and the present invention also provides preparation method and the purposes of this pharmaceutical composition.
The present invention relates to a kind of pharmaceutical composition for the treatment of mastofibroma, it is the preparation being prepared from by the crude drug of following weight proportioning:
15～18 parts of Radix Salviae Miltiorrhizaes, 12～15 parts of Radix Angelicae Sinensis, 15～18 parts of Radix Scrophulariaes, 12～15 parts of Spica Prunellaes, 12～15 parts of Fructus Forsythiaes, 10～12 parts, Semen Persicae, 6～9 parts, Flos Carthami, 4～6 parts of Rhizoma Chuanxiongs, 10～12 parts of Rhizoma Bolbostematiss, 25～30 parts of Concha Ostreae, 8～10 parts of Rhizoma Cyperis, 8～10 parts of Radix Curcumaes, 8～10 parts of Radix Bupleuri, 8～10 parts of the Radix Paeoniae Albas, Radix Platycodonis 4～6,8～10 parts of Radix Achyranthis Bidentataes, 4～6 parts, Radix Glycyrrhizae.
Further, it is the preparation being prepared from by the crude drug of following weight proportioning:
15 parts of Radix Salviae Miltiorrhizaes, 12 parts of Radix Angelicae Sinensis, 18 parts of Radix Scrophulariaes, 15 parts of Spica Prunellaes, 15 parts of Fructus Forsythiaes, 12 parts, Semen Persicae, 9 parts, Flos Carthami, 6 parts of Rhizoma Chuanxiongs, 12 parts of Rhizoma Bolbostematiss, 30 parts of Concha Ostreae, 10 parts of Rhizoma Cyperis, 10 parts of Radix Curcumaes, 10 parts of Radix Bupleuri, 10 parts of the Radix Paeoniae Albas, Radix Platycodonis 6,10 parts of Radix Achyranthis Bidentataes, 6 parts, Radix Glycyrrhizae.
Wherein, it be by the primary crude drug powder of described crude drug or the water of crude drug or/and extractive with organic solvent is active component, add that pharmaceutically acceptable adjuvant or complementary composition are prepared into pharmaceutically conventional preparation.
Further, described preparation is oral formulations.
Further, described preparation is tablet, capsule, soft capsule, granule, pill, drop pill, oral liquid, Sublingual spray, injection.
The present invention has also offered a kind of method of preparing above-mentioned compositions, and it comprises the steps:
A, take the crude drug of weight proportion;
The primary crude drug powder of b, each crude drug or the water of crude drug, or/and extractive with organic solvent is active component, add pharmaceutically acceptable adjuvant or complementary composition to be prepared into pharmaceutically conventional preparation.
Further, the organic solvent described in b step is 60-95%v/v ethanol.
The present invention also provides the purposes of aforementioned pharmaceutical compositions in the medicine of preparation treatment mastofibroma.
Generally acknowledged that at present " organic conception ", " determination for the treatment of based on pathogenesis obtained through differentiation of symptoms and signs ", " compound recipe use ", " compound compatibility medication is as used military forces " are the most scientific the most several large advantages of the traditional Chinese medical science, wherein " compound compatibility medication is as used military forces " is the original theory of Chinese medicine of very science.Each medicine tight compatibility all linked with one another as arrayed troops for battle in traditional Chinese medical science prescription is its effective means that is better than Western medicine formula.Tcm prescription theory is thought, each prescription, not only need to select the appropriate compatibility of suitable medicine according to etiology and pathogenesis, also should meet the basic structure of prescription simultaneously, the i.e. prescription compatibility theory of " monarch, minister, help, make ", the prescription compatibility of so-called " monarch, minister, help, make " is exactly that it is based upon the scientific matching on the comprehensive judgement basis of disease pathogenesis.In medical square tube cross too many levels, many target spots and integrate the biological mechanism regulating, this heavy serious disease of coronary heart disease is recuperated under medical treatment, can obtain therapeutic effect better than Western medicine, that more green natural has no side effect, and this curative effect is to be based upon on the accurate instruction of the original theory of above-mentioned traditional Chinese medical science tradition, prescription of the present invention is just being followed this principle.
In pharmaceutical composition of the present invention, Radix Salviae Miltiorrhizae, Radix Angelicae Sinensis, Radix Scrophulariae, Radix Paeoniae Alba nourshing blood and promoting blood circulation, the source of foster as a means of moistening " woman is congenital " (liver), and so blood circulation promoting and blood stasis dispelling and nourish blood and grow Tianjin, can anti-purification stagnation resolvation painful abdominal mass and just hinder, therefore taking Radix Salviae Miltiorrhizae as monarch (medicine), GUISHAO Radix Scrophulariae is left hall ministerial drug, carries on a shoulder pole this main task.Semen Persicae, Flos Carthami, Rhizoma Chuanxiong, Radix Achyranthis Bidentatae blood circulation and removing stasis, can assist monarch drug potentiation, therefore send as right hall ministerial drug.Breast breast is the meridians compress by liver, qi as the commander of blood again, the capable blood of gas, blood is not brought about the desired sensation not push away and is lived, and gas must not moisten not all right by blood, Rhizoma Chuanxiong is blood system gas medicine, Rhizoma Cyperi, Radix Curcumae, Radix Bupleuri are good at and are regulated the flow of vital energy soothing the liverly, and the Radix Paeoniae Alba is good at easing the affected liver, can assist a ruler in governing a country the present invention and not only have a merit of vital energy regualting and blood circulation-promoting, and have the effect of conditioning Liver Channel, therefore can be used as the adjuvant drug on left road.Kind Rhizoma Bolbostematis, the Spica Prunellae for the treatment of newborn disease is longer than removing summer-heat softening the hard mass digestion sucutaneous nodule, Concha Ostreae, the Fructus Forsythiae of dispersing swelling and dissipating binds, the eliminating stagnation of the joining hard masses softening and resolving Radix Scrophulariae of scrofula that disappears, effect is more outstanding, so same with the adjuvant drug that is right wing, can assist a ruler in governing a country right hall ministerial drug Semen Persicae, Flos Carthami, Rhizoma Chuanxiong, the thin knot of Radix Achyranthis Bidentatae repercussive, nodule in the breast must be fallen apart.Radix Platycodonis upwards, can draw that each medicine is up to be reached in breast breast; Radix Achyranthis Bidentatae is by evil blood, and property is downward, the descending and tonneau breast network of the heresy that can draw stasis; Radix Glycyrrhizae and all medicines of middle coordination; Therefore Radix Platycodonis, Radix Achyranthis Bidentatae, Radix Glycyrrhizae be the negative mission that makes medicine all.So match, the stasis of blood that not only can promoting the circulation of blood is stagnant, the condensing of loose expectorant, and the strongly fragrant addiction that can vent one's spleen again, invigorates blood circulation and does not consume liver blood, and the Eradicates stasis of blood can also tissue regeneration promoting, and fullness and oppression sensation in the epigastrium due to accumulation of phlegm goes and newborn ruton, and liver blood must moisten and nodules of the breast must fall apart, and can make nodule in the breast remove, and breast is pacified again.
Below respectively organize flavour of a drug post clearly demarcated, complement each other, give full play to the exclusive compound compatibility medication of Chinese medicine as the analyze mentally sexology research methodology marrow of row army as structuring the formation, there is good therapeutic effect for mastofibroma, can effectively alleviate its symptom, for clinical application provides a kind of new selection.
Detailed description of the invention
The preparation of embodiment 1 medicine of the present invention
Get 15 grams of Radix Salviae Miltiorrhizaes, 12 grams of Radix Angelicae Sinensis, 18 grams of Radix Scrophulariaes, 15 grams of Fructus Forsythiaes, 15 grams of Spica Prunellaes, 12 grams, Semen Persicae, 9 grams, Flos Carthami, 6 grams of Rhizoma Chuanxiongs, 12 grams of Rhizoma Bolbostematiss, 30 grams of Concha Ostreae, 10 grams of Rhizoma Cyperis, 10 grams of Radix Curcumaes, 10 grams of Radix Bupleuri, 10 grams of the Radix Paeoniae Albas, Radix Platycodonis 6,10 grams of Radix Achyranthis Bidentataes, 6 grams, Radix Glycyrrhizae.Each flavour of a drug take according to quantity, and Concha Ostreae is smashed to pieces, and Radix Curcumae, Rhizoma Bolbostematis are smashed up, and add enough water purification this three medicine that is decocted first, more than after boiling, slow fire decocts half an hour again, more lower all the other each medicines, after boiling, decoct again approximately 12 minutes to 15 minutes, collect decocting liquid; Medicinal residues decoct with water 2 times again, merge decocting liquid each time, obtain decoction.
The preparation of embodiment 2 pharmaceutical compositions of the present invention
Get 18 grams of Radix Salviae Miltiorrhizaes, 15 grams of Radix Angelicae Sinensis, 15 grams of Radix Scrophulariaes, 12 grams of Fructus Forsythiaes, 12 grams of Spica Prunellaes, 10 grams, Semen Persicae, 6 grams, Flos Carthami, 4 grams of Rhizoma Chuanxiongs, 10 grams of Rhizoma Bolbostematiss, 25 grams of Concha Ostreae, 8 grams of Rhizoma Cyperis, 8 grams of Radix Curcumaes, 8 grams of Radix Bupleuri, 8 grams of the Radix Paeoniae Albas, Radix Platycodonis 4,8 grams of Radix Achyranthis Bidentataes, 4 grams, Radix Glycyrrhizae.First, with after 70%v/v ethanol extraction 2 times, merge alcohol extract, medicinal residues boil 2 times with decocting again, merge decocting liquid.After respectively alcohol extract, decocting liquid being concentrated, mix, then add suitable dextrin, soluble starch, granulate, obtain granule.
The preparation of embodiment 3 pharmaceutical compositions of the present invention
Get 16 grams of Radix Salviae Miltiorrhizaes, 14 grams of Radix Angelicae Sinensis, 16 grams of Radix Scrophulariaes, 13 grams of Fructus Forsythiaes, 13 grams of Spica Prunellaes, 11 grams, Semen Persicae, 8 grams, Flos Carthami, 5 grams of Rhizoma Chuanxiongs, 11 grams of Rhizoma Bolbostematiss, 28 grams of Concha Ostreae, 9 grams of Rhizoma Cyperis, 9 grams of Radix Curcumaes, 9 grams of Radix Bupleuri, 9 grams of the Radix Paeoniae Albas, Radix Platycodonis 5,9 grams of Radix Achyranthis Bidentataes, 5 grams, Radix Glycyrrhizae.First, with after 50-60%v/v ethanol extraction 3 times, merge alcohol extract, reclaim ethanol, then add suitable dextrin, soluble starch, granulate, tabletting, obtains tablet.
The preparation of embodiment 4 pharmaceutical compositions of the present invention
Get granule prepared by embodiment 2, filled capsules, obtains capsule.
The preparation of embodiment 5 pharmaceutical compositions of the present invention
Get 15 grams of Radix Salviae Miltiorrhizaes, 12 grams of Radix Angelicae Sinensis, 18 grams of Radix Scrophulariaes, 15 grams of Fructus Forsythiaes, 15 grams of Spica Prunellaes, 12 grams, Semen Persicae, 9 grams, Flos Carthami, 6 grams of Rhizoma Chuanxiongs, 12 grams of Rhizoma Bolbostematiss, 30 grams of Concha Ostreae, 10 grams of Rhizoma Cyperis, 10 grams of Radix Curcumaes, 10 grams of Radix Bupleuri, 10 grams of the Radix Paeoniae Albas, Radix Platycodonis 6,10 grams of Radix Achyranthis Bidentataes, 6 grams, Radix Glycyrrhizae.First, with after 95%v/v ethanol extraction 2 times, merge alcohol extract, medicinal residues boil 2 times with decocting again, merge decocting liquid.After respectively alcohol extract, decocting liquid being concentrated, mix, leave standstill, filter, filtrate adds appropriate correctives and antibacterial, is prepared into oral liquid.
The preparation of embodiment 6 pharmaceutical compositions of the present invention
Get decoction prepared by embodiment 1, leave standstill, get supernatant, after concentrating, dry, pulverize, for subsequent use; Get appropriate Macrogol 4000, after melting, above-mentioned medicated powder is added in melting substrate, insulation at 75-85 DEG C; Adopt various pill dripping machine, drip inside/outside footpath and a speed appropriateness, splashed in dimethicone, collects drop pill, obtains drop pill.
Prove beneficial effect of the present invention by pharmacodynamics test below.
Clinical (outpatient service) treatment situation of test example medicine of the present invention
(1) accept patient's situation for medical treatment
According to inventor's clinical practice of more than 30 year, with Drug therapy mammary gland fibroadenoma patient 15 examples of embodiment 1, obtain comparatively satisfied curative effect.Treatment time: according to the difference of the concrete conditions such as each conditions of patients weight, age size, physical strength and to some extent difference, generally can alleviate at two or three week, about 3 weeks～12 months, symptom, sign, health check-up can recover normal or normal.Mammary gland fibroadenoma is apt to occur in 18 to 25 years old outside upper quadrant of sexual function female breast in vigorous period (other age brackets women also can occur), and except occurring lump, patient is conventionally without obvious subjective symptoms.Adenoma is often single-shot, also has multiple person.Rounded or the oval of adenoma, diameter is comparatively common with 1～3 centimetre of person, also has smaller or greater person, even visible huge person.It is strong but pliable in texture, clear border, and smooth surface, movable good, without adhesion, mobility is large with skin and surrounding tissue, and that touches has a sense of slip, and axillary lymph is tied without enlargement.Adenoma is many without pain, and also, without touching a tender spot, only 14% has mild pain, while being paroxysm or accidental or menstruation, excites.The common poor growth of lump, can the several years unchanged, but can increase rapidly age of sucking in gestation, can there is in now sarcomatous change in individual other, but its big or small character does not generally change with menstrual cycle.Only a few patient's nipple has limpid discharge, accounts for 0.75%.
(2) treatment standard
Recovery from illness: symptom, sign disappearance (mammary gland fibroadenoma is that lump in breast and pain disappear completely).
Evident in efficacy: symptom, sign obviously alleviate (mammary gland fibroadenoma is that lump volume-diminished is over half, has slight tenderness, and after premenstrual, anger and fatigue, the degree of mastalgia obviously alleviates before treating).
There is certain effect: patient's symptom, sign slightly alleviate (mammary gland fibroadenoma is the deliquescing of lump quality, half that volume-diminished is not enough, after premenstrual, anger and fatigue, mastalgia alleviates to some extent).
Invalid: symptom etc. all remain unchanged, do not improve completely.
(3) Therapeutic Method
1, the made decoction of embodiment 1, every bu is taken for 3 times, and serveing on 10 is a course for the treatment of, can drug withdrawal between the course for the treatment of and the course for the treatment of 1 day, as waiting, diarrhoea also answers drug withdrawal if suffer from other new diseases.
2, note also science conditioning daily life, observe some necessary points for attention, as:
(1) keep good phychology and healthy life, learning style.Overcome bad dietary habit and hobby, work regularly, learn.Note the stable of emotion with and happy, be sure not excitement, get angry, depressed, worried, increase the weight of the stasis of Liver Channel and the irregular operating of breast breast tissue (" stagnation of QI is the expectorant blood coagulation stasis of blood " " alluvial becomes to tie ").Emotional lability can suppress the ovulation function of ovary, occurs that progesterone reduces, and estrogen is increased relatively, causes primary disease.
(2) avoid using and contain estrogenic facial cream and medicine.Some women are for beautifying skin, and life-time service contains estrogenic facial cream, and of a specified duration can bring out primary disease.
(3) want in good time marriage and childbirth.Although encourage late marriage and late childbirth, should not be excessively slow.Women marries for best 25 years old to 28 years old, and fertility before 30 years old is crossed I and educated also unfavorable aristogenesis.Secondly, note contraception, because conceived 6 weeks time, estrogen and progestogen that embryo villi is secreted can stimulate mammary gland; If do artificial abortion, the mammary gland tissue of hypertrophy is difficult for atrophy, more difficult reinstatement, and abnormal mammary gland is easily fallen ill.
(4) sexual life is wanted appropriateness regular.Breast is said women, is not only suckling organ, is also sexual organ simultaneously.When sexual life, breast can change by generating period.Gestation, suckling are a kind of physiological regulation to mammary gland function, and therefore, marriage and childbirth in good time, suckling, be favourable to mammary gland; On the contrary, if 30 years old above unmarried, do not educate or women that suckling is few easily ill.
(5) cherish breast, often health check-up.The women of each all ages and classes section should adhere to Condition of Breast Self-examination, after menstruation monthly totally, carries out; Within 30 years old, above women carries out a health check-up to mammary gland training every year, and within 40 years old, above women asks specialist's health check-up once every half a year, accomplishes early to find early treatment.
(3) adopt a correct attitude towards mastopathy, can not hide one's sickness for fear for the treatment of.Find will seek medical advice immediately after breast has lump, partner treatment.Although mammary gland fibroma is benign tumor, also there is the possibility cancerating, particularly between pregnant age of sucking, the growth of tumor body is very fast or older, and the course of disease is longer, or with cyclomastopathy or multiple relapse person, more should enhance your vigilance, medical in time, prevents change of illness state.Feminine half should accomplish that early early treatment, the udder health of special concern oneself are early found in prevention.
(4) therapeutic outcome
Between thirties years, with medicine composite for curing mammary gland fibroadenoma patient of the present invention 15 examples, obtain good curative effect, by above-mentioned science conditioning daily life, sincerely abided by points for attention, can obtain good result.
By above-mentioned treatment standard, in 15 routine patients, there are 8 example recoveries from illness, cure rate reaches 53.33%; 4 examples are evident in efficacy, reach 26.67%; 1 example has certain effect, accounts for 6.67%; 2 routine DeGrains (invalid), account for 13.33%.Total effective rate reaches 86.67%.
Model case
Patient, female, 20 years old, tall, body was healthy and strong.Patient finds that unintentionally the outside upper quadrant of own right breast has the hard lump of multiple Semen Glycines sizes, but pain not, through looking into, is examined as mammary gland fibroadenoma.After the moon in ten days, patient seeks tcm diagnosis and treatment.The outside upper quadrant of its right breast approximately more than 10 tumor pieces, are oval ball-type or ball-shaped, oncontacting pain, and that lays one's hand on is strong but pliable in texture, and smooth surface is movable good, and clear border, has the sense of slip, and axillary lymph knot has no enlargement.Except this, remaining without other symptoms, tongue arteries and veins is also normal, only chi slightly a little less than.Already clarify a diagnosis, give pharmaceutical composition of the present invention (prepared by embodiment 1), advise between the new stadium such as its menstrual period, diseases caused by exogenous pathogenic factor and temporarily withdraw, and sternly abide by the method for administration of above-mentioned " Therapeutic Method " it " 1 " and the science of " 2 " conditioning and points for attention.Patient abides by and advises, and adheres to taking medicine nearly October, unexpectedly makes softening, the dissipation gradually of tumor piece, and symptom, sign are all reformed often.After this, annual health check-up, recurrence that so far there are no.
In sum, drug regimen composition formula of the present invention is precise and appropriate, can effectively treat mammary gland fibroadenoma (or alleviating its patient's condition), and the toxic and side effects of having avoided chemical drugs to have, for clinical application provides a kind of new selection.
Claims (8)
1. a pharmaceutical composition for the treatment of mammary gland fibroma, is characterized in that: it is the preparation being prepared from by the crude drug of following weight proportioning:
15～18 parts of Radix Salviae Miltiorrhizaes, 12～15 parts of Radix Angelicae Sinensis, 15～18 parts of Radix Scrophulariaes, 12～15 parts of Spica Prunellaes, 12～15 parts of Fructus Forsythiaes, 10～12 parts, Semen Persicae, 6～9 parts, Flos Carthami, 4～6 parts of Rhizoma Chuanxiongs, 10～12 parts of Rhizoma Bolbostematiss, 25～30 parts of Concha Ostreae, 8～10 parts of Rhizoma Cyperis, 8～10 parts of Radix Curcumaes, 8～10 parts of Radix Bupleuri, 8～10 parts of the Radix Paeoniae Albas, Radix Platycodonis 4～6,8～10 parts of Radix Achyranthis Bidentataes, 4～6 parts, Radix Glycyrrhizae.
2. pharmaceutical composition according to claim 1, is characterized in that: it is the preparation being prepared from by the crude drug of following weight proportioning:
15 parts of Radix Salviae Miltiorrhizaes, 12 parts of Radix Angelicae Sinensis, 18 parts of Radix Scrophulariaes, 15 parts of Spica Prunellaes, 15 parts of Fructus Forsythiaes, 12 parts, Semen Persicae, 9 parts, Flos Carthami, 6 parts of Rhizoma Chuanxiongs, 12 parts of Rhizoma Bolbostematiss, 30 parts of Concha Ostreae, 10 parts of Rhizoma Cyperis, 10 parts of Radix Curcumaes, 10 parts of Radix Bupleuri, 10 parts of the Radix Paeoniae Albas, Radix Platycodonis 6,10 parts of Radix Achyranthis Bidentataes, 6 parts, Radix Glycyrrhizae.
3. pharmaceutical composition according to claim 1 and 2, it is characterized in that: it be by the primary crude drug powder of described crude drug or the water of crude drug or/and extractive with organic solvent is active component, add that pharmaceutically acceptable adjuvant or complementary composition are prepared into pharmaceutically conventional preparation.
4. according to the pharmaceutical composition described in claim 1-3 any one, it is characterized in that: described preparation is oral formulations.
5. pharmaceutical composition according to claim 4, is characterized in that: described preparation is tablet, capsule, soft capsule, granule, pill, drop pill or oral liquid.
6. a method of preparing compositions described in claim 1-5 any one, is characterized in that: it comprises the steps:
A, take the crude drug of weight proportion;
The primary crude drug powder of b, each crude drug or the water of crude drug, or/and extractive with organic solvent is active component, add pharmaceutically acceptable adjuvant or complementary composition to be prepared into pharmaceutically conventional preparation.
7. preparation method according to claim 6, is characterized in that: the organic solvent described in b step is 60-95%v/v ethanol.
8. the purposes of pharmaceutical composition in the medicine of preparation treatment mastofibroma described in claim 1-5 any one.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410151841.2A CN103933475B (en) | 2014-04-15 | 2014-04-15 | A kind of pharmaceutical composition treating mammary gland fibroma and its production and use |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410151841.2A CN103933475B (en) | 2014-04-15 | 2014-04-15 | A kind of pharmaceutical composition treating mammary gland fibroma and its production and use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103933475A true CN103933475A (en) | 2014-07-23 |
| CN103933475B CN103933475B (en) | 2016-08-17 |
Family
ID=51181531
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410151841.2A Expired - Fee Related CN103933475B (en) | 2014-04-15 | 2014-04-15 | A kind of pharmaceutical composition treating mammary gland fibroma and its production and use |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103933475B (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109010690A (en) * | 2018-09-13 | 2018-12-18 | 张财宝 | A kind of compound anti-cancer medicine composition |
| CN117244035A (en) * | 2023-11-20 | 2023-12-19 | 北京老年医院 | Pharmaceutical composition for treating breast nodules and preparation method thereof |
-
2014
- 2014-04-15 CN CN201410151841.2A patent/CN103933475B/en not_active Expired - Fee Related
Non-Patent Citations (1)
| Title |
|---|
| 李贵兴: "《新编中兽医学》", 31 January 2012, article "夏枯草汤" * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109010690A (en) * | 2018-09-13 | 2018-12-18 | 张财宝 | A kind of compound anti-cancer medicine composition |
| CN117244035A (en) * | 2023-11-20 | 2023-12-19 | 北京老年医院 | Pharmaceutical composition for treating breast nodules and preparation method thereof |
| CN117244035B (en) * | 2023-11-20 | 2024-02-02 | 北京老年医院 | Pharmaceutical composition for treating breast nodules and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103933475B (en) | 2016-08-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103071128B (en) | Externally-applied plaster for curing dysmenorrhea | |
| CN103585478B (en) | Chinese medicinal composition for treating hypertension | |
| CN101897882A (en) | Medicament for treating and breast lobular hyperplasia and cyst | |
| CN103933475B (en) | A kind of pharmaceutical composition treating mammary gland fibroma and its production and use | |
| CN103599404A (en) | Traditional Chinese medicinal decoction for treating cervical spondylosis | |
| CN100352483C (en) | Externally applied medicine for treating mammary glands hyperplasia and preventing mammary cancer | |
| CN104288303A (en) | Traditional Chinese medicine for treating cardiovascular and cerebrovascular diseases | |
| CN103585609A (en) | Traditional Chinese medicine composition for treating dysmenorrhea and preparation method thereof | |
| CN103212037A (en) | Traditional Chinese medicine for treating female endocrine disorder and preparation method of traditional Chinese medicine | |
| CN102626502A (en) | Traditional Chinese medicinal composition for treating mammary gland hyperplasia | |
| CN104958693A (en) | Traditional Chinese medicine for treatment of hyperplasia of mammary glands | |
| CN102813746B (en) | Traditional Chinese medicine composition for treating numbness of fingers | |
| CN102283973B (en) | Traditional Chinese medicine plaster for treating benign tumor and reducing weight and preparation method thereof | |
| CN101396534B (en) | Traditional Chinese medicine for treating lobular hyperplasia of mammary gland | |
| CN104352867A (en) | Traditional Chinese medicine composition for treating gestational depression | |
| CN104856524B (en) | A kind of antihypertensive health care medicated pillow | |
| CN102580004B (en) | Chinese medicinal composition for treating male erectile dysfunction | |
| CN102641420B (en) | Pharmaceutical composition for treating coronary heart disease | |
| CN102028887B (en) | Traditional Chinese medicine for treating hyperplasia of cervical vertebra | |
| CN101618091B (en) | Traditional Chinese medicine preparation for treating stony uterine mass, ovarian cyst, sterility and breaks in gynaecology | |
| CN105311396A (en) | Traditional Chinese medicine preparation for treating hypomenorrhea caused by thin endometrium | |
| CN104740193A (en) | Traditional Chinese medicine composition for treating neck-shoulder muscle strain syndrome and preparation method of traditional Chinese medicine composition | |
| CN104800384A (en) | Oral traditional Chinese medicine composition for treating climacteric arthritis | |
| CN103585377B (en) | Oral medicine for treating breast nodules | |
| CN103041017A (en) | Traditional Chinese medicine preparation for treating functional uterine bleeding and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20160817 Termination date: 20190415 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |